sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has revealed an opening position disclosure relating to its stakes in Avadel Pharmaceuticals plc. This disclosure, filed under Rule 8.3 of the Irish Takeover Panel Act, 1997, is part of standard protocol for entities with over 1% interest in relevant securities. As of 12 December 2025, Vanguard holds 5,606,686 ordinary shares, representing a 5.76% interest in Avadel.
Recent transactions by Vanguard include the purchase of 11,271 shares at a price of 21.36 USD per unit and the sale of 96 shares at the same price. No cash-settled or stock-settled derivative transactions were reported.
The submission indicated no existence of indemnities, options, or agreements influencing Vanguard's dealings regarding Avadel's securities. Additionally, no further agreements or understandings impacting voting rights or future securities transactions were disclosed.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.